CMRX Chimerix Inc Earnings per share for the last twelve months

CMRX (Chimerix Inc.) - company brandmark

Chimerix, Inc. (CMRX) develops anti-tumor agents through partnerships with public and private entities. The company complies with environmental chemical disposal regulations and strives for leadership in clinical trials. The annual net income per share trend visualizes the market consensus, while -0.99 determines the current status of the parameter, helping investors adjust their portfolios in a timely manner.

CMRX (Chimerix, Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 04/26/2025

Chimerix Inc. - analytical breakdowns and key metrics (CMRX)

- current quotes and average value forecast:
Price Chart Chimerix, Inc.|CMRX - Average Forecast Price
- market capitalization data:
Market Value Chimerix, Inc.|CMRX - Business Value
- shareholders' equity book value data:
Book Value per Share Chimerix|CMRX - Company Net Assets|Market Value to Book Value Ratio chimerix.com|CMRX - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Chimerix, Inc.|CMRX - Long-Term Debt to Equity|Short-Term Debt to Equity Chimerix, Inc|CMRX - Company Cumulative Debt|Debts to Book Capitalization Chimerix, Inc.|CMRX - Long-Term Indebtedness|Company Current Liabilities Chimerix|Quick Liquidity Indicator chimerix.com
- net income and valuation multiples indicators:
CMRX - Final Profit|Future Profit Chimerix, Inc.|CMRX - Market Price to Net Income Ratio|Forward P/E Multiple Chimerix|CMRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Chimerix, Inc.|CMRX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Chimerix|CMRX - Earnings per share for the trailing year|Quarterly EPS earnings growth chimerix.com|CMRX - Earnings growth in current year|Net earnings per share growth forecast for next year Chimerix, Inc.
Basic company analysis:Chimerix, Inc. (CMRX)
Mass-produced product of Chimerix, Inc

Government contracts with BARDA and oncology partnerships provide Chimerix, Inc. (CMRX) with strategic resilience. This indicator reflects the aggregate annual net income distributed per common share based on 10-K and 10-Q data. It is critical for investors to assess real capital efficiency while excluding reporting lags. Analysis requires a balance between market sentiment and fundamental value. Net income per share dynamics allow for the timely identification of asset overvaluation.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals, Inc.|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year beyondspringpharma.com BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology Holdings Inc. LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals)|CLRB (Cellectar Corp) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (canfite.com)|Aprea - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (Kazia Therapeutics)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana (NCNA)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months